Gibb, A. A., Murray, E. K., Huynh, A. T., Gaspar, R. B., Ploesch, T. L., Bedi, K., … Elrod, J. W. (2022). Glutaminolysis is Essential for Myofibroblast Persistence and In Vivo Targeting Reverses Fibrosis and Cardiac Dysfunction in Heart Failure. Circulation, 145(21), 1625–1628. https://doi.org/10.1161/CIRCULATIONAHA.121.057879

Gibb, Andrew A., Emma K. Murray, Anh T. Huynh, Ryan B. Gaspar, Tori L. Ploesch, Ken Bedi, Alyssa A. Lombardi, et al. “Glutaminolysis is Essential for Myofibroblast Persistence and In Vivo Targeting Reverses Fibrosis and Cardiac Dysfunction in Heart Failure.” Circulation 145, no. 21 (May 24, 2022): 1625–28. https://doi.org/10.1161/CIRCULATIONAHA.121.057879.

Gibb AA, Murray EK, Huynh AT, Gaspar RB, Ploesch TL, Bedi K, et al. Glutaminolysis is Essential for Myofibroblast Persistence and In Vivo Targeting Reverses Fibrosis and Cardiac Dysfunction in Heart Failure. Circulation. 2022 May 24;145(21):1625–8.

Gibb, Andrew A., et al. “Glutaminolysis is Essential for Myofibroblast Persistence and In Vivo Targeting Reverses Fibrosis and Cardiac Dysfunction in Heart Failure.” Circulation, vol. 145, no. 21, May 2022, pp. 1625–28. Pubmed, doi:10.1161/CIRCULATIONAHA.121.057879.

Gibb AA, Murray EK, Huynh AT, Gaspar RB, Ploesch TL, Bedi K, Lombardi AA, Lorkiewicz PK, Roy R, Arany Z, Kelly DP, Margulies KB, Hill BG, Elrod JW. Glutaminolysis is Essential for Myofibroblast Persistence and In Vivo Targeting Reverses Fibrosis and Cardiac Dysfunction in Heart Failure. Circulation. 2022 May 24;145(21):1625–1628.